- Home
- SCHW vs GILD Comparison
SCHW vs GILD Comparison
Compare SCHW & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCHW
- GILD
- Stock Information
- Founded
- SCHW 1971
- GILD 1987
- Country
- SCHW United States
- GILD United States
- Employees
- SCHW N/A
- GILD N/A
- Industry
- SCHW Investment Bankers/Brokers/Service
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCHW Finance
- GILD Health Care
- Exchange
- SCHW Nasdaq
- GILD Nasdaq
- Market Cap
- SCHW 168.4B
- GILD 140.8B
- IPO Year
- SCHW 1987
- GILD 1992
- Fundamental
- Price
- SCHW $96.11
- GILD $118.37
- Analyst Decision
- SCHW Buy
- GILD Buy
- Analyst Count
- SCHW 17
- GILD 24
- Target Price
- SCHW $102.71
- GILD $114.26
- AVG Volume (30 Days)
- SCHW 8.5M
- GILD 6.4M
- Earning Date
- SCHW 10-14-2025
- GILD 08-07-2025
- Dividend Yield
- SCHW 1.12%
- GILD 2.67%
- EPS Growth
- SCHW 54.29
- GILD 496.80
- EPS
- SCHW 3.72
- GILD 5.01
- Revenue
- SCHW $21,626,000,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- SCHW $21.71
- GILD $1.91
- Revenue Next Year
- SCHW $10.00
- GILD $3.75
- P/E Ratio
- SCHW $25.85
- GILD $23.62
- Revenue Growth
- SCHW 16.32
- GILD 3.81
- 52 Week Low
- SCHW $61.16
- GILD $72.89
- 52 Week High
- SCHW $99.59
- GILD $121.83
- Technical
- Relative Strength Index (RSI)
- SCHW 51.91
- GILD 59.20
- Support Level
- SCHW $95.28
- GILD $108.54
- Resistance Level
- SCHW $99.42
- GILD $121.83
- Average True Range (ATR)
- SCHW 1.79
- GILD 2.48
- MACD
- SCHW -0.31
- GILD 0.52
- Stochastic Oscillator
- SCHW 32.82
- GILD 73.97
About SCHW Charles Schwab Corporation (The)
Charles Schwab is one of the largest retail-oriented financial services companies in the US, with $10.1 trillion in client assets across its brokerage, banking, asset-management, custody, financial advisory, and wealth-management businesses at year-end 2024. While best known for its retail brokerage offering, Schwab generates the lion's share of its revenue and profits through its Charles Schwab Bank and asset-management segments. The firm is a dominant player in registered investment advisor custody, with over 40% market share, and has recently pushed into wealth management with robo-advisory, direct indexing, and other managed-investment solutions.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).